UCB receives CHMP positive opinion for Cimzia® (certolizumab pegol) in severe active axial spondyloarthritis

UCB has announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending extending the European Union marketing authorization for the use of Cimzia® (certolizumab pegol) in the treatment of adult patients with severe active axial spondyloarthritis (axSpA)...
Back Pain News From Medical News Today

Related Content